Latest Licensing And Partnerships News

BPH Global has launched a focused R&D collaboration with Temasek Polytechnic to develop seaweed-based bio-stimulants aimed at boosting growth and yields in Southeast Asia's oil palm and rice sectors. Early talks are also underway for a production facility in Indonesia to commercialize these innovations.

HeraMED has partnered with RMIT University and the Digital Health CRC to develop AI-driven maternity care models focused on culturally diverse populations, aiming to improve pre-term delivery risk prediction and personalised care.

Echo IQ’s application for a key US procedural code was rejected but the company plans a swift resubmission, maintaining confidence in its US commercial rollout.

Algorae Pharmaceuticals has partnered with Peter MacCallum Cancer Centre to validate AI-predicted drug combinations across multiple cancer types, aiming to accelerate its oncology pipeline development.

Unibail-Rodamco-Westfield and Cenomi Centers have entered a decade-long exclusive partnership to bring the Westfield brand to Saudi Arabia’s premier shopping centres, aiming to reshape retail experiences across the Kingdom’s largest cities.

Starpharma reports steady progress in its DEP® drug development programs, launches new marketing campaigns in key regions, and maintains a strong cash position of $17.2 million as it refines clinical strategies and partnerships.

Opyl Limited reports strong progress in AI-driven clinical trial optimisation with active commercial initiatives, strategic partnerships, and a planned capital raise to support growth amid tight cash reserves.

Arizona Lithium Limited is set to deploy Koch Technology Solutions’ first commercial-scale Li-Pro DLE unit at its Prairie Project, marking a pivotal advancement in lithium extraction from oilfield brines.

Invex Therapeutics reports a significant reduction in net loss for H1 FY2025 alongside promising pre-clinical data for Exenatide in Alzheimer’s Disease models.

Vectus Biosystems reports completion of Phase Ib trials for its lead drug VB0004 and a robust cash position bolstered by a significant R&D tax refund, setting the stage for licensing discussions.